- Pyxis Oncology press release (NASDAQ:PYXS): Q4 GAAP EPS of -$1.32 misses by $1.02.
- As of December 31, 2024, Pyxis Oncology had cash and cash equivalents, including restricted cash, and short-term investments, of $128.4 million.
- The company believes that its current cash, cash equivalents, and short-term investments will be sufficient to fund its operations into the second half of 2026.
